Rewiring immunity: CAR-T cells as a paradigm shift in hematologic oncology - PubMed
3 hours ago
- #CAR-T cell therapy
- #Hematologic malignancies
- #Cancer immunotherapy
- Hematologic malignancies affect over 1.5 million individuals in the United States.
- CAR-T cell therapy represents a paradigm shift in treating hematologic malignancies.
- Seven CAR-T cell therapies have been approved by the U.S. FDA for conditions like B-cell lymphoma, multiple myeloma, and acute lymphoblastic leukemia.
- CAR-T therapy shows robust response rates and effective clearance of malignant cells.
- Challenges include manufacturing timelines, geographic access limitations, and high financial costs.
- The review provides an updated synthesis of clinical outcomes, treatment-related toxicities, and access barriers.